BS_DGTPWJ59
Neurocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurocytoma
- overall_survival_months
- 100.45992115637318
- age_years
- 24.463
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.411
- OXIDATIVE_PHOSPHORYLATION+0.273
- MYC_TARGETS_V1+0.272
- UNFOLDED_PROTEIN_RESPONSE+0.269
- DNA_REPAIR+0.255
- SPERMATOGENESIS+0.148
- KRAS_SIGNALING_DN+0.108
- ADIPOGENESIS+0.103
- PROTEIN_SECRETION+0.072
- UV_RESPONSE_UP+0.052
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.571
- IL6_JAK_STAT3_SIGNALING-0.568
- ALLOGRAFT_REJECTION-0.534
- INFLAMMATORY_RESPONSE-0.522
- TGF_BETA_SIGNALING-0.506
- INTERFERON_GAMMA_RESPONSE-0.505
- TNFA_SIGNALING_VIA_NFKB-0.504
- COMPLEMENT-0.425
- IL2_STAT5_SIGNALING-0.401
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.398
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TGW6HC4X | Neurocytoma | — | 0.928 |
| 2 | SRR1432321 | GTEX | — | 0.917 |
| 3 | SRR1340420 | GTEX | — | 0.908 |
| 4 | SRR1316874 | GTEX | — | 0.905 |
| 5 | BS_RCC8BXVE | medulloblastoma | — | 0.905 |
| 6 | SRR1441118 | GTEX | — | 0.903 |
| 7 | SRR1315842 | GTEX | — | 0.902 |
| 8 | SRR1499442 | GTEX | — | 0.893 |
| 9 | SRR1498702 | GTEX | — | 0.893 |
| 10 | SRR1467364 | GTEX | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.411 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.273 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.272 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.269 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.255 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.148 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.108 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.103 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.072 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.052 | Idelalisib | — uncovered |